Armstrong Henry H Associates Inc buys $397,169 stake in Pfizer (PFE)

Pfizer (PFE) : Armstrong Henry H Associates Inc scooped up 482 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 10,778 shares of Pfizer which is valued at $397,169.Pfizer makes up approximately 0.08% of Armstrong Henry H Associates Inc’s portfolio.

Other Hedge Funds, Including , K.j. Harrison Partners Inc reduced its stake in PFE by selling 20,000 shares or 16.14% in the most recent quarter. The Hedge Fund company now holds 103,880 shares of PFE which is valued at $3,827,978. Pfizer makes up approx 2.00% of K.j. Harrison Partners Inc’s portfolio. First National Bank Of Hutchinson added PFE to its portfolio by purchasing 6,289 company shares during the most recent quarter which is valued at $231,750. Pfizer makes up approx 0.14% of First National Bank Of Hutchinson’s portfolio.Atalanta Sosnoff Capital reduced its stake in PFE by selling 47,895 shares or 3.52% in the most recent quarter. The Hedge Fund company now holds 1,312,703 shares of PFE which is valued at $48,373,106. Pfizer makes up approx 1.57% of Atalanta Sosnoff Capital’s portfolio.Highland Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 38,579 additional shares and now holds a total of 308,905 shares of Pfizer which is valued at $11,330,635. Pfizer makes up approx 0.95% of Highland Capital Management’s portfolio.Loring Wolcott Coolidge Fiduciary Advisors Llpma boosted its stake in PFE in the latest quarter, The investment management firm added 10,797 additional shares and now holds a total of 78,856 shares of Pfizer which is valued at $2,863,261. Pfizer makes up approx 0.06% of Loring Wolcott Coolidge Fiduciary Advisors Llpma’s portfolio.

Pfizer opened for trading at $36.68 and hit $36.95 on the upside on Friday, eventually ending the session at $36.89, with a gain of 0.60% or 0.22 points. The heightened volatility saw the trading volume jump to 2,15,13,828 shares. Company has a market cap of $223,732 M.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *